Antiangiogenic properties of fibstatin, an extracellular FGF-2-binding polypeptide.

Carine Bossard (1) , Loic van den Berghe (1) , Henrik Laurell (1) , Caroline Castano (1) , Martine Cerutti (1) , Anne-Catherine Prats (1) , Hervé Prats (1)

1 Hormones, facteurs de croissance et physiopathologie vasculaire

By using the two-hybrid system with basic fibroblast growth factor (FGF-2) as bait, we isolated and characterized fibstatin, an endogenous M(r) 29,000 human basement membrane-derived inhibitor of angiogenesis and tumor growth. Fibstatin, a fragment containing the type III domains 12-14 of fibronectin, was produced as a recombinant protein and was shown to inhibit the proliferation, migration, and differentiation of endothelial cells in vitro. Antiangiogenic activity of fibstatin was confirmed in a Matrigel angiogenesis assay in vivo, and electrotransfer of the fibstatin gene into muscle tissue resulted in reduced B16F10 tumor growth. Taken together, these results suggest that fibstatin could act as a powerful molecule for antiangiogenic therapy.

Mots clés: anti-angiogenesis; FGF-2; Fibronectin; tumor inhibition

Domaines: Médecine humaine et pathologie

Carine Bossard, Loic van den Berghe, Henrik Laurell, Caroline Castano, Martine Cerutti, et al.. Antiangiogenic properties of fibstatin, an extracellular FGF-2-binding polypeptide.. Cancer Research, 2004, 64 (20), pp.7507-12. ⟨10.1158/0008-5472.CAN-04-0287⟩. ⟨hal-00307739⟩